Comparison of nicorandil and atenolol in stable angina pectoris

https://doi.org/10.1016/0002-9149(90)91129-TGet rights and content

Abstract

The efficacy of nicorandil was compared with atenolol in 37 patients with chronic stable angina using a randomized, placebo-controlled, parallel study design. After a single-blind placebo phase, patients were randomized to receive nicorandil or atenolol using a double-dummy technique. Patients took nicorandil 10 mg twice daily or atenolol 50 mg once daily for the first 3 weeks, and if no adverse effects were encountered they took nicorandil 20 mg twice daily or atenolol 100 mg once daily, for the final 3-week phase. Treadmill exercise tests were performed at the end of each treatment phase immediately before and 2 hours after the morning dose of medication. Groups were demographically similar. Placebo exercise times were 7.06 (0.60) minutes (mean ± standard error of the mean) in the nicorandil group and 6.81 (0.47) minutes in the atenolol group. After 6 weeks, improvements in exercise time were before dosing: +1.47 (0.40) minutes with nicorandil (p < 0.005) and +1.33 (0.29) minutes with atenolol (p < 0.001). Improvements after therapy was administered were +2.45 (0.41) minutes with nicorandil (p < 0.001) and +2.37 (0.43) minutes with atenolol (p < 0.0001). Whereas, the predose peak exercise double product (heart rate X systolic blood pressure mm Hg/100) was reduced with atenolol (−43.6 units; p < 0.001), an increase (+7.56 units; difference not significant) was noted with nicorandil. One patient taking atenolol and 5 taking nicorandil developed persistent headaches. One subject with severe 3-vessel coronary artery disease had fatal myocardial infarction within 3 days of starting nicorandil, 10 mg twice daily. Nicorandil and atenolol produce comparable improvement in exercise time in patients with stable angina but the former does not reduce myocardial oxygen demand. This new agent may be beneficial in patients with angina in whom β blockers are contraindicated, although headache may be a problem in a significant minority of patients.

References (18)

There are more references available in the full text version of this article.

Cited by (36)

  • Refractory Angina

    2018, Chronic Coronary Artery Disease: A Companion to Braunwald's Heart Disease
  • Refractory Angina

    2017, Chronic Coronary Artery Disease: A Companion to Braunwald's Heart Disease
  • Management standards for stable coronary artery disease in India

    2016, Indian Heart Journal
    Citation Excerpt :

    Nicorandil functions via activating ATP–sensitive potassium channels and promoting systemic venous and coronary vasodilatation, eventually it causes a rise in coronary blood flow, a decrease in after-load, preload and oxidative injury.105 The efficacy of nicorandil in patients with stable angina has been compared to placebo, alone or in combination with standard anti-anginal medications in randomised trials, including the Impact Of Nicorandil in Angina (IONA) randomised study,106 the Study of Women's health Across the Nation (SWAN) group study,107 and some Asian studies.108–110 A meta-analysis evaluating the short-term efficacy of nicorandil compared with anti-anginal drugs for stable angina found that nicorandil did not show a significant reduction of weekly angina frequency.

  • Management of Patients With Refractory Angina: Canadian Cardiovascular Society/Canadian Pain Society Joint Guidelines

    2012, Canadian Journal of Cardiology
    Citation Excerpt :

    The anti-anginal properties of nicorandil have been known for more than 30 years. A series of small RCTs suggested that nicorandil can exert an anti-ischemic effect comparable to conventional doses of β-blockers, oral nitrates, and calcium antagonists in patients with stable effort angina pectoris.151-158 Because of the large individual variations in the rates of anginal attack and exercise duration on treadmill stress test, these studies were underpowered to detect any significant differences between nicorandil and other anti-anginal agents.

View all citing articles on Scopus
View full text